Sponsor & Developer Portfolio
National Institute of Allergy and Infectious Diseases (NIAID)
Clinical development pipeline, platform architecture, and registered trial tracking for National Institute of Allergy and Infectious Diseases (NIAID) vaccine candidates.
1
Candidates
1
Target Diseases
1
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 1
Platform Technologies
mRNA: 1
Target Pathogens & Indications
COVID-19
Vaccine Pipeline Candidates (1)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-moderna-mrna-1273-national-institute-of-allergy-and-infectious-d
Moderna mRNA-1273
Target: COVID-19
Platform: mRNA
Key Milestone: Primary completion (most advanced trial): 2023-06-22 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.